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Abstract: Current strategies to treat pelvic organ prolapse (POP) or stress urinary incontinence 18 
(SUI), include the surgical implantation of vaginal meshes. Recently, there has been multiple reports 19 
of issues generated by these meshes conventionally made of poly(propylene). This material is not 20 
the ideal candidate due to its mechanical properties leading to complications such as chronic pain 21 
and infection. In the present manuscript, we propose the use of an alternative material, 22 
thermoplastic polyurethane (TPU), loaded with an antibiotic in combination with fused deposition 23 
modelling (FDM) to prepare safer vaginal meshes. For this purpose, TPU filaments containing 24 
levofloxacin (LFX) in various concentrations (e.g., 0.25, 0.5, and 1%) were produced by extrusion. 25 
These filaments were used to 3D print vaginal meshes. The printed meshes were fully characterized 26 
trough different test/analysis such as fracture force studies, attenuated total reflection-Fourier 27 
transform infrared, thermal analysis, scanning electron microscopy, X-ray microcomputed 28 
tomography (μCT), release studies and microbiology testing. The results showed that LFX was 29 
uniformly distributed within the TPU matrix, regardless the concentration loaded. The mechanical 30 
properties showed that poly(propylene) (PP) is a tougher material with lower elasticity than TPU 31 
which seemed to be a more suitable material due to its elasticity. In addition, the printed meshes 32 
showed a significant bacteriostatic activity on both Staphylococcus aureus and Escherichia coli cultures 33 
minimising the risk of infection after implanting them. Therefore, the incorporation of LFX to the 34 
TPU matrix can be used to prepare anti-infective vaginal meshes with enhanced mechanical 35 
properties compared with current PP vaginal meshes. 36 
Keywords: 3D printing; fused deposition modeling; extrusion; vaginal meshes; mechanical 37 
properties; drug release, anti-infective devices; pelvic organ prolapse; stress urinary incontinence 38 
1. Introduction 39 
Pelvic organ prolapse (POP) and stress urinary incontinence (SUI), are two very common 40 
disorders affecting 30-40% of women worldwide, mainly with the increasing of age [1]. Since the 41 
population is gradually older, with the passage of time there will be an increase in the incidence of 42 
POP of 46% between 2010 and 2050 [2]. Although they are not lethal diseases, these two pathologies 43 
negatively influence the quality of life of women, including their social, sexual, physical and 44 
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psychological well-being [1,3]. The implantation of meshes to reinforce soft tissue defects and provide 45 
an additional support to prolapsed organs and viscera is a common approach to treat POP and SUI 46 
[4]. 47 
Vaginal meshes are commonly made of poly(propylene) (PP) or polyester, materials that already 48 
used for hernia repair [5,6]. These materials are safe for hernia repair, but its safety was not properly 49 
tested for pelvic floor applications [5]. However, they were approved by the US FDA [5,6]. Since 50 
approval, multiple cases of complications associated to vaginal meshes have been reported [7]. The 51 
main problem for these meshes is the different structure and motility of the pelvic floor when 52 
compare with the abdominal wall. In addition to this, important movements and morphological 53 
changes occur during a woman's life, and as a result, the material used to repair the pelvic floor must 54 
be not only biocompatible, but also able to tolerate the stress and tension associated with such a 55 
dynamic environment and at the same time flexible and elastic [5].  56 
PP is the main polymer used for the production of synthetic meshes for POP surgery due to its 57 
chemical stability and non-biodegradable property [8]. However, complications such as adhesion to 58 
the viscera and high inflammatory response found in the repair of the pelvic floor [8] have led 59 
researchers to study alternative solutions. Biodegradable/bioresorbable polymers, such as 60 
poly(caprolactone) or poly(lactic acid) (PLA), have been used for mesh implant application with 61 
mixed results [9–11]. In some cases, this type of implants can display mechanical failures due to their 62 
degradation. For example, PLA94 can present mechanical problems after 8 months [11]. Accordingly, 63 
non-biodegradable polymers seem to be a safer approach. Recently, it was reported that 64 
poly(urethane)-based meshes were safer and more suitable than PP for vaginal meshes production 65 
[12,13]. Accordingly, polyurethane-based polymers seem to be the ideal candidate for this 66 
application. 67 
In addition to safer materials, new manufacturing methods can provide benefit to the resulting 68 
medical devices. A potential technology to produce the aforementioned meshes is 3D printing. This 69 
technology allows clinicians to prepare devices adapted to patient’s anatomy and requirements [14–70 
17]. Furthermore, a wide range of materials can be used for 3D printing applications. These materials 71 
include PLA, PP or nylon. PLA has been extensively used for biomedical applications and for 3D 72 
printing applications [18–20]. PLA is one of the most widely used material for 3D printing 73 
(specifically for fused deposition modelling) [20,21]. However, as described before, due to its 74 
biodegradable nature is not the ideal candidate for vaginal mesh preparation. Interestingly, 75 
poly(urethane), a promising material for pelvic floor surgery, has been used before for 3D printing 76 
applications [14]. 77 
The flexibility of 3D printing also allows to combine polymeric materials with drugs to prepare 78 
drug eluting devices [14,19,22]. This is extremely useful for implantable devices that have a relatively 79 
high risk of infection [14,19,23]. If the device is loaded with antibiotics this will prevent bacterial 80 
colonisation of its surface preventing infections [14,19]. There are a wide variety of techniques within 81 
3D printing technology [16]. In the present work, fused deposition modelling (FDM) was used. This 82 
technique relies on the extrusion of a polymeric filament trough a hot nozzle to prepare objects. To 83 
combine the polymers with drugs within the filament hot melt extrusion (HME) is needed. For this 84 
purpose, a drug substance and the selected polymer are melted inside a rotating screw to mix them 85 
and subsequently extrude them to form a filament [15]. This filament will be subsequently used for 86 
FDM applications. 87 
The aim of this work is to develop a new generation of vaginal mesh implants. For this purpose, 88 
meshes will be prepared using thermoplastic poly(urethane) (TPU) and they will be loaded with an 89 
antibacterial agent, levofloxacin (LFX) (drug commonly used to treat urinary infections), using fused 90 
deposition modelling (FDM). This technique is the most common type of 3D printing. Three different 91 
filaments of TPU containing 0.25%, 0.5%, and 1% of LFX were prepared through single hot-melt 92 
extruder in order to be used for the 3D Printing FDM process. Mechanical strength, drug release and 93 
antimicrobial properties were evaluated to confirm the efficiency of the meshes. 94 
 95 
 96 
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2. Materials and Methods  97 
2.1. Materials 98 
Elastollan® thermoplastic polyurethane (TPU) 80A pellets were used for this study and kindly 99 
provided by DistruPol Ltd (A Univar Company, Co Dublin). Castor oil was purchased from Ransom, 100 
LFX ((S)-9-fluoro-2,3-dihydro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-7H-pyrido[1,2,3-de]-1,4-101 
benzoxazine-6-carboxylic acid) >98% was obtained by Sigma Aldrich, and the phosphate buffered 102 
saline (PBS) tablets pH 7.4 from Merck. The PP filament (2.85 mm diameter) was purchased from 103 
Verbatim (Japan). 104 
2.2. Preparation of TPU filaments containing LFX 105 
In order to 3D print meshes, filaments were prepared using the Hot-Melt Extrusion (HME) 106 
technique by combining the TPU with LFX. An oil method was used to ensure a homogeneous 107 
distribution of the drug on the pellet’s surface. TPU pellets (30 gr) were placed in 50 mL Falcon tubes 108 
and castor oil (30 μL) was added and vortexed for a few min in order for the pellets to be covered 109 
homogeneously by the oil. The pellets were transferred to a new 50 mL Falcon tubes to avoid drug 110 
wastage that could remain attached due to excess oil on the wall of the previous tubes, as previously 111 
reported [14]. Then, LFX was added in ratio of 0.25% w/w and the tube was vortexed in order to coat 112 
the pellets. Finally, the coated pellets were introduced in the filament extruder (3Devo, Utretch, The 113 
Netherlands) using an extrusion speed range of 3-5 rpm and a filament diameter of 2.85 mm. The 114 
temperature was regulated directly during the extrusion over four heaters between 170°C and 200°C. 115 
The same procedure was performed for preparing filaments containing 0.5% and 1% of LFX. The 116 
filament formed using only TPU, which used for the preparation of blank meshes, was manufactured 117 
introducing directly the pellets into the extruder. Formulations with their compositions to 118 
manufacture the filaments are presented in the Table 1.  119 
Table 1. Composition of TPU filaments containing LFX. 120 
Formulations TPU (g) Castor oil (uL) LFX (g) 
TPU 30 - - 
0.25% LFX 30 30 0.075 
0.50% LFX 30 30 0.15 
1.00% LFX 30 30 0.3 
 121 
2.3. Preparation of 3D printed meshes containing LFX 122 
Meshes were printed with the drug-loaded and unloaded filaments that previously prepared 123 
with the extruder, using an Ultimaker 3 (Ultimaker B.V., Geldermalsen, The Netherlands) fused 124 
filament fabrication (FFF) system, furnished of two extruders with a 0.4 mm nozzle, and Cura® 125 
software. Different models were designed through a CAD-based software. For the TPU meshes, the 126 
layer height was set at 0.1 mm with the in-fill setting on the software at 100%. The printing 127 
temperature was set at 190 ºC and the printing speed was 12 mm/s. However, for the PP meshes, the 128 
printing temperature was set between 195 and 208 ºC and the printing speed was 25 mm/s. These PP 129 
meshes were manufactured using the filament obtained from Verbatim. 130 
2.4. Characterization of 3D printed meshes 131 
2.4.1. Mechanical properties 132 
Meshes with 50 mm x 10 mm size were printed, and the fracture force was studied with 133 
TA.XTplus texture analyser (Stable Micro Systems, Surrey, UK). Each sample was vertically fixed 134 
with two clamps, with a distance between them of 40 mm, and stretched at a rate of 5 mm/s up to 200 135 
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mm. The experiment was repeated 4 times for each sample. The force/displacement curves were 136 
recorded, and different parameters were obtained. The elastic limit of the resulting meshes were 137 
obtained using the 0.2% offset method [24]. Additionally, the tensile stiffness was calculated from the 138 
force/displacement curves as the slope of the initial linear region [25]. 139 
2.4.2 Fourier Transform Infrared (FT-IR) spectroscopy 140 
The Fourier Transform Infrared (FT-IR) spectra of 1 cm x 1 cm meshes were recorded through a 141 
Spectrum Two™ instrument (Perkin Elmer, Waltham, MA, USA). The spectra were recorded between 142 
4000 cm−1 and 600 cm−1 applying a resolution of 4 cm−1; total of 32 scans were collected.  143 
2.4.3. Thermogravimetric analysis (TGA) 144 
As the elastomer was subjected to high temperatures during the 3D-printing process, the 145 
thermal degradation behaviour of the polymer was examined. Thermogravimetric analysis (TGA) 146 
was performed to measure the weight loss of the TPU meshes containing LFX. For this purpose, a 147 
small fragment of these meshes (3 mg and 10 mg) was used. TGA was performed using a Q500 148 
Thermogravimetric analysis (TA instruments, Bellingham, WA, USA). Scans were run from room 149 
temperature to 550 °C, at a speed rate of 10° C/min under a nitrogen flow rate of 50 ml/min  150 
2.4.4. Scanning electron microscopy (SEM) 151 
Scanning electron microscopy was used in order to investigate the surface morphologies of the 152 
1 cm x 1 cm 3D-printed meshes containing 0.25, 0.5 and 1% of LFX compared with the blank mesh, 153 
using samples before and after a 14-days release study. The meshes were examined using a Hitachi 154 
TM3030 SEM (Tokyo, Japan), and images were taken with a magnification of 50x, 60x, 80x, 300x and 155 
500x. Additionally, a Leica EZ4 D digital microscope (Leica, Wetzlar, Germany) was used to examine 156 
the presence or not of drug aggregates within the extruded materials. 157 
2.4.5. X-ray microcomputed tomography (μCT) 158 
X-ray Microcomputed Tomography imaging was performed on 3D printed meshes using the 159 
same approach previously reported [14]. Briefly, all the samples were analysed by using a Bruker 160 
Skyscan 1275, with a Hamamatsu L11871 source (40kV, 250μA). The meshes were mounted vertically 161 
on dental wax and positioned at 57.5 mm from the source, where camera to source distance was 286 162 
mm. No filter was applied for an exposure time of 49ms. The images generated were 1536x1944 pixels 163 
with a resolution of 17μm per pixel. A total of 1056 images were taken in 0.2° steps around one 164 
hemisphere of the sample, with an average of 3 frames taken at each rotation step. Attenuation 165 
thresholding was conducted manually, in order to eliminate speckle around the samples. The same 166 
thresholding was applied within Bruker’s CTan software, where the samples were further processed. 167 
2.5. In vitro drug release studies 168 
The release profile for the LFX was defined conducting release studies that allowed calculating 169 
the amount of drug eluted from the LFX-loaded meshes. Each sample was placed in Eppendorf’s 170 
with 2 mL of PBS. Subsequently the Eppendorf’s were located in a shaking incubator at 37°C at 40 171 
rpm. After 1, 2, 4, 24, 48, 72, 96 and 120 hours the sample was removed from the tube, dried and 172 
relocated in a new Eppendorf containing 2 mL of fresh PBS. Further studies performed also in new 173 
samples for 7 and 14 days. The concentration of LFX was calculated after measuring the UV 174 
absorbance of the solution taken from the Eppendorf’s with a UV-visible plate reader (PowerWave 175 
XS Microplate Spectrophotometer, Bio-Tek, Winooski, VT, USA) at a wavelength of 292 nm as 176 
previously reported [26]. For each concentration (control, 0.25, 0.5 and 1%), 1 cm x 1 cm meshes were 177 
used in series of 4. 178 
 179 
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2.6. In vitro microbiological analysis 180 
Printed meshes (1 cm × 1 cm × 0.1 cm) were tested for inhibitory effect on bacterial cultures of 181 
Staphylococcus aureus NCTC 10788 (Gram-positive) and Escherichia coli NSM59 (Gram-negative). E. 182 
coli and S. aureus are examples of bacteria that can cause a variety of community-and hospital-183 
acquired infections. This in vitro microbiological analysis was performed according to a previous 184 
published work, with some modifications [14]. Briefly, bacteria were grown overnight at 37 °C in 185 
Mueller-Hinton (MH) broth. For each bacterium, 50 μL of the overnight culture were added to 5 mL 186 
of MH soft agar. This mixture was vortexed and then poured on top of the MH agar plate. Finally, 187 
meshes were placed in the centre of the plate and incubated for 24 h at 37 °C. The inhibition zone 188 
caused for both bacterial strains was then measured in mm. Moreover, inoculated plates for each 189 
bacterial strain were also incubated as a positive control. The results were expressed as mean ± 190 
standard deviation of 5 replicates.  191 
2.7. Statistical Analysis 192 
Quantitative data were expressed as a mean ± standard deviation, n ≥ 3. The statistical analysis 193 
was performed using a one-way analysis of variance (ANOVA), p < 0.05 was considered to be 194 
statistically significant. 195 
3. Results 196 
3.1. Preparation and characterisation of TPU filaments and meshes containing LFX 197 
The extrusion of the TPU pellets containing the different LFX concentrations were used to 198 
produce smooth and flexible filaments of 2.85 mm in diameter (Figure 1A). The resulting materials 199 
contained different amounts of LFX ranging from 0.25 to 1% (w/w). All the filaments prepared using 200 
hot-melt extrusion showed the same translucent colour. No visible aggregates of drug were seen 201 
within the extruded materials. Considering that LFX is a white solid this suggest that the antibiotic 202 
was mixed with the molten TPU within the extrusion process. Moreover, the results suggest that TPU 203 
and LFX can be mixed properly using a single screw extruder following the pellet coating method. 204 
Otherwise, a more complicated equipment such as a twin-screw extruder will be required to mix the 205 
drug and the polymer properly.  206 
 207 
Figure 1. Microscopy image of the TPU and LFX loaded TPU filaments (A). FTIR spectra of LFX, TPU and TPU 208 
containing 1% of LFX (B). TGA of TPU and TPU containing 1% LFX (C). 209 
 210 
FT-IR and TGA were used to try to establish if there were any interaction between TPU and LFX. 211 
The FT-IR spectra of the materials containing LFX showed the same peaks that the blank TPU (Figure 212 
1B). The drug loadings selected for the present work was too low to be able to produce any changes 213 
in FT-IR spectra. However, TGA measurements (Figure 1C) shows that when LFX was combined 214 
with TPU using hot melt extrusion the resulting material presented different thermal degradation 215 
behaviour. Filaments containing LFX started to degrade at higher temperatures than blank TPU 216 
filaments. In order to compare both materials, the onset temperatures (Tonset) were measured. Tonset 217 
denotes the temperature at which the weight loss begins (5% weight loss). The onset temperature for 218 
TPU was 280˚C while the recorded onset temperature for TPU containing 1% of LFX was 303˚C. As 219 
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mentioned before this temperature differences can be attributed to interactions between the TPU and 220 
the LFX. 221 
 222 
 223 
Figure 2. CAD 3D image of the two layer meshes with its dimensions (A). Representative image showing the 224 
flexibility of a TPU-based mesh (B). Image of TPU and TPU loaded with LFX 3D printed meshes (C). SEM images 225 
of TPU and LFX loaded TPU 3D printed meshes (D). 226 
 227 
The TPU filaments previously described were used to prepare different types of surgical meshes. 228 
These designs were prepared using Computer Aided Software and subsequently prepared using 229 
fused deposition modelling. Figure 2A shows the designs used to prepare the meshes with their 230 
dimensions. Moreover, Figure 2C shows some 1x1 cm mesh prototypes produced using the filaments 231 
described in section 3.1. As expected, all these prototypes presented the same appearance as LFX was 232 
completely mixed with the TPU. These resulting meshes are flexible as can be seen in Figure 2B. These 233 
results can be corroborated by using SEM (Figure 2D). The microscopy images showed that all the 234 
resulting meshes showed the same structure and no signs of drug aggregation within the surface of 235 
the devices. 236 
The 3D printed samples were analysed by using a Bruker Skyscan 1172 system (Figure 3), in 237 
order to investigate samples’ topology as well as drug distribution within their architecture. As it 238 
could be seen in Figure 3B-D, the incorporation of LFX did not affect the 3D printed mesh 239 
morphology, which resulted very similar for all the analysed samples and comparable to the one of 240 
pure TPU80 (Figure 3A). 241 
In addition, as shown in the representative reconstruction images, the meshes exhibited the same 242 
topology. Particularly, even at the highest concentration of LFX (Figure 3D), no traces of particles 243 
were detected within the printed meshes, thus indicating a uniform distribution of the drug, 244 
regardless the concentration tested. Moreover, according to this outcome it was further demonstrated 245 
the effectiveness of the manufacturing process from drug incorporation to 3D printed sample 246 
fabrication.  247 
 248 
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 249 
Figure 3. μCT reconstructions in the xz plane of pure TPU80 mesh (A) and TPU80 mesh loaded with 0.25% (B), 250 
0.5% (C) and 1% (D) of LFX [scale bar = 2 mm]. 251 
3.2. Mechanical Characterisation of LFX 3D printed meshes 252 
The mechanical properties of two-layered mesh implants prepared using fused deposition 253 
modelling were measured. Figure 4 shows representative force/displacement graphs for the prepared 254 
meshes. All the TPU-based meshes showed similar profiles. The first region of the graph showed 255 
elastic behaviour (initial linear section of the graph) and then when higher forces are applied the 256 
meshes showed plastic deformation (see Figures 4A and 4B). It is important to note that they did not 257 
fully break under the testing conditions (200 mm of elongation) in some cases they show some minor 258 
fractures during the last stages of the test (Figure 4B). However, this does not happen consistently in 259 
all the meshes. This was observed only in two cases. It is important to note that these partial fractures 260 
happened after the mesh elongated more than 3 times its original size. On the other hand, meshes 261 
made of PP were prepared to compare the obtained results with the material typically used for mesh 262 
implant manufacturing. PP showed a different mechanical behaviour than TPU-based meshes. PP 263 
meshes failed during the test as they showed a clear and reproducible fracture point (Figure 4A).  264 
 265 
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 266 
Figure 4. Force/displacement graphs obtained for TPU meshes containing 1% LFX and PP meshes (A). 267 
Force/displacement graph showing a small fracture for a TPU-based mesh (B). The arrow indicates the fracture 268 
point. 269 
The elastic limit and the tensile stiffness were evaluated from the force/displacement curves. The 270 
elastic limit was measured from the force/displacement curves using the 0.2% offset method. This 271 
value represents the force required to produce a 0.2% of plastic deformation of the meshes. All TPU-272 
based meshes showed elastic limits around 1 N (Table 2). Moreover, statistical analysis showed that 273 
there were no significant differences between all these values (p > 0.05). These results suggest that 274 
LFX loadings of up to 1% (w/w) did not alter the mechanical properties of TPU. This is important for 275 
the applications as TPU was selected due to its elasticity as opposed to conventional PP meshes. 276 
Polypropylene meshes showed significantly higher elastic limit than the TPU-based meshes (p < 0.05). 277 
This is consistent with the nature of the material that is not an elastic material as opposed to TPU. 278 
Finally, the tensile stiffness of the mesh implants was evaluated. Again, the results showed that all 279 
TPU-based meshes showed equivalent values of tensile stiffness ca. 0.4 N/mm (p > 0.05). Moreover, 280 
PP meshes showed significantly higher values of tensile stiffness (p < 0.05). These values showed that 281 
PP required higher forces to elongate within the elastic region of the material. Accordingly, PP is a 282 
tougher material with lower elasticity. Again, TPU seems a more suitable approach for mesh implant 283 
manufacture due to its elasticity. 284 
Table 2. Mechanical properties obtained for the 3D printed meshes formed by two layers. 285 
  LFX Content 
(%) 
Elastic Limit 
(N) 
Tensile Stiffness 
(N/mm) 
Fracture Force 
(N) 
Elongation at 
break (mm) 
TPU 0.00 1.2 ± 0.4 0.44 ± 0.12 - - 
LFX 0.25% 0.25 1.0 ± 0.2 0.32 ± 0.06 - - 
LFX 0.50% 0.50 1.1 ± 0.1 0.37 ± 0.04 - - 
LFX 1.00% 1.00 1.3 ± 0.2 0.45 ± 0.08 - - 
PP 0.00 6.5 ± 0.2 6.05 ± 0.83 15. 42 ± 0.66 129 ± 7 
3.3. LFX release from 3D printed meshes 286 
 Figure 5 shows the LFX release from 3D printed meshes. Figure 5A shows the LFX released as a 287 
function of time for the 3D printed meshes. The prepared meshes are capable of providing sustained 288 
release of LFX for at least 3 days. Additionally, it can be seen that all the release profiles showed the 289 
similar shapes. The total amount of LFX released after 5 days (Figure 5B) increased with drug loading. 290 
However, there is a significant increase in the drug loading when the LFX loading increased from 291 
0.25% to 0.5% (p > 0.05). When drug loading increased from 0.5% to 1% a small increment in drug 292 
release was observed. However, statistical analysis revealed that this different is not statistically 293 
significant (p < 0.05). Accordingly, it can be hypothesised that LFX could be interacting with TPU 294 
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within the meshes and this prevent higher drug release. This is consistent with the results described 295 
in section 3.1. These results are more obvious when the release was expressed as percentage of the 296 
initial drug loading (Figure 5C). This graph showed some interesting results. The percentage of drug 297 
release increase with drug loading up to a maximum. This maximum was obtained for meshes 298 
containing 0.5% of LFX. Subsequently, the percentage of drug release decreases when drug loading 299 
was increased up to 1% (p < 0.05). This showed that LFX/TPU interactions are taking place and 300 
reducing drug release. 301 
 302 
Figure 5. LFX release as a function of time for different LFX loaded 3D printed meshes (A). Maximum LFX 303 
release expressed in μg (B) and percentage (C) as a function of initial LFX drug loading. 304 
3.4. Antimicrobial properties of LFX loaded 3D printed meshes 305 
Printed meshes (1 cm × 1 cm × 0.1 cm) containing different LFX concentrations were tested for 306 
antimicrobial effect on a bacterial culture of S. aureus and E. coli in order to evaluate good examples 307 
of bacteria that are involved in a variety of community-and hospital-acquired infections. The results 308 
of the zone of inhibition are presented in the Figure 6. In this case, the zone of inhibition indicates 309 
that both used bacteria either at the surface of the meshes or even for an area extending outwards 310 
from the mesh’s surface is inhibited. All the meshes containing LFX showed a clear zone of inhibition 311 
in both S. aureus and E. coli plates. As expected, the results showed no zone of inhibition in plates 312 
containing the control meshes without LFX.  313 
The zones of inhibition in both S. aureus and E. coli plates were increased by increasing the 314 
amount of LFX. The diameter of the zone of inhibition in the S. aureus plates with TPU meshes 315 
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containing LFX ranged from 25.5 ± 1.4 mm to 28.6 ± 0.8 mm, and from 25.2 ± 0.9 to 28.2 ± 0.8 in the E. 316 
coli plates. Statistical analysis showed that there were significant differences between the zones of 317 
inhibition caused by meshes containing 0.25% and 0.5% or 1% LFX (p < 0.05). This behaviour was 318 
observed for both cultures, S. aureus and E. coli. However, there were no significant differences in the 319 
zone of inhibition caused by meshes containing 0.5% and 1% LFX (p > 0.05). Once again, this trend 320 
was observed for both bacterial strains. These results are is in line with the obtained drug release 321 
profile for the meshes containing LFX (Figure 5A). In addition, when the zones of inhibition of E. coli 322 
and S. aureus were compared for the same concentration of LFX (0.25%, 0.5% and 1%), no significant 323 
differences were observed for any LFX concentration (p > 0.05). Therefore, it can be inferred that LFX 324 
had the same impact on both bacterial strains, which are the most frequent causes of many common 325 
bacterial infections.  326 
Figure 6. Correlation between the diameter of the zone of inhibition of S. aureus (A) and E. coli (B) and the 327 
concentration of LFX. Agar plates showing the zone of inhibition of meshes without LFX (TPU) and containing 328 
1% of LFX for both bacterial strains, S. aureus (C) and E. coli (D). 329 
4. Discussion 330 
Historically, PP has been the choice material for pelvic floor repair since 1995 [13]. However, it 331 
has been shown that this material is not the ideal candidate for these applications due to the 332 
mechanical mismatch between the elastic paravaginal tissue and the strong and rigid PP [27]. 333 
Accordingly, the mechanical properties of PP mesh have generated multiple problems after mesh 334 
implantation. According to the US FDA the use of PP mesh for pelvic floor repair can lead to serious 335 
complications associated with tissue erosion [28,29]. The ideal material for the production of pelvic 336 
floor repair mesh implants should possess elasticity and strength [12].  337 
The present work describes the use of fused deposition modelling for the production of mesh 338 
implants for potential pelvic organ reconstructive surgery. TPU was selected as the ideal candidate 339 
for this purpose due to its elasticity and previously demonstrated biocompatibility [12,13,18]. This 340 
material has been used before for mesh implant manufacturing showing superior capabilities than 341 
PP implants [12,13]. Additionally, TPU was combined with an antibiotic drug to prevent infection of 342 
this implantable material after surgery. Mesh-related infections are not common but when they occur 343 
they can compromise patients’ well-being even leading to excision of the mesh implant or sepsis [30]. 344 
LFX was the antibiotic chosen for this application. In a previous work it was loaded in meshes 345 
prepared using electrospinning for hernia repair [26]. This antibiotic was combined with TPU using 346 
hot-melt extrusion to prepare filaments for further FDM applications. The materials showed 347 
homogeneous distribution of the drug. This was achieved using a single screw extruder coating the 348 
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TPU pellets with LFX. This method has been previously used with successful results [14,19,31,32]. 349 
This is a quick way to obtain good mixtures between the drug and the polymer using a single screw 350 
extruder that is more accessible than a complicated and expensive twin-screw extruder. Figure 1A 351 
shows that the drug was properly dispersed within the material. FTIR results did not show any 352 
noticeable peak shift (Figure 1B). As mentioned before this can be due to the low drug loading. Similar 353 
behaviour was reported before for the combination of TPU and tetracycline or poly(urethane) and 354 
ciprofloxacin, a drug similar to LFX [14,33]. On the other hand, TGA results (Figure 1C) shows that 355 
there was interaction between LFX and TPU. Similar behaviour was reported when TPU was 356 
combined with tetracycline, ciprofloxacin or Schiff base additives [14,33,34]. It has been proposed 357 
that the C=O groups present in the TPU urethane groups can stablish non-covalent interactions with 358 
the drug. 359 
The interaction of LFX with TPU can explain the behaviour obtained in the drug release profiles. 360 
In these experiments, meshes containing 1% of LFX showed a lower percentage of LFX released from 361 
the meshes than meshes containing 0.5% of LFX. The interactions between the polymer and the drug 362 
prevents a higher drug release. This has been observed previously for other drugs such as 363 
dipyridamole loaded into polyurethane [35]. Similarly, lower drug loadings (0.25% LFX) showed low 364 
release too. TPU is a non-degradable/hydrophobic polymer and, accordingly, the drug cargo located 365 
inside the material will not be released. Finally, the TPU meshes described in the present work are 366 
capable of providing releases of LFX for at least 3 days. A previously published work describing the 367 
use of electrospinning to prepare poly(caprolactone) surgical meshes loaded with LFX (0.5%) showed 368 
that this system was capable of providing drug release over l day. However, the nature of the mesh 369 
forming polymer was completely different. 370 
This work was not only focused on the development of safer materials for mesh implant 371 
manufacturing but the use of techniques that allow clinicians to customize the mesh to patient’s needs 372 
in a simple way. Therefore, FDM seems like an ideal technique for this purpose. TPU based meshes 373 
were successfully prepared using FDM (Figure 2). As expected, all the meshes had the same 374 
appearance and now noticeable drug aggregation was observed (Figure 2). Computed tomography 375 
was used to confirm drug distribution within the mesh matrix. Again, the results suggested that the 376 
drug was uniformly distributed within the mesh. In a previous study computed tomography 377 
suggested that the combination of similar TPU with tetracycline showed some drug accumulation in 378 
certain parts of the material [14]. In this case, tetracycline was distributed all over the material, but 379 
some accumulation was observed using computed tomography. 380 
The observed mechanical properties of the resulting meshes proved the initial approach: the 381 
resulting materials showed elastic behaviour unlike PP. TPU-based meshes showed stiffness values 382 
ca. 0.4 N/mm while commercial PP meshes showed values ranging between 2 and 6 N/mm [25]. The 383 
design of the commercial meshes is different than the one proposed in the present paper but the 384 
testing conditions for these commercial meshes were similar. Some comparisons can be made. In 385 
order to compare the effect of the material in the mechanical properties, PP meshes were prepared 386 
using the same design used for the TPU based materials. Obviously, this PP is not exactly the same 387 
than the one used in conventional meshes but it is a good example to compare the behaviour of both 388 
materials. The stiffness results obtained for PP (ca. 6 N/mm) was higher than the one obtained for 389 
TPU meshes and the Force/displacement profile was completely different. Moreover, the stiffness 390 
values obtained for PP meshes were slightly higher than the previously reported results for 391 
commercial PP meshes (up to 5.3715 N/mm) [25]. However, the PP meshes tested in this work showed 392 
a different design than the commercial meshes. The mechanical characteristics of the material are 393 
important as it has been reported that materials with higher flexibility seem to adhere and conform 394 
to the tissues better than more rigid/stiffener meshes [36]. The design and size of the meshes can be 395 
hanged easily due to the versatility of FDM.  396 
The 3D-printed meshes had a bacteriostatic activity on both S. aureus and E. coli cultures (Figure 397 
6). This fact supports the premise that the extrusion and 3D printing processes did not affect the 398 
bacteriostatic activity of LFX. The risk of toxicity of these coated medical devices could be an 399 
important issue. Therefore, the possibility to print these medical devices using a small amount of the 400 
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desired drug, and still have bacteriostatic activity, clearly minimizes the risk of toxicity in the patients. 401 
For instance, medical devices such as thermoplastic polyurethane (TPU) catheters were 3D-printed 402 
using up to 1% of tetracycline [14], thereby minimizing the risk of infection. Also, Weisman et al. [31] 403 
in a different study, reported the possibility to print poly(lactic acid) (PLA) catheters using up to 2.5% 404 
of gentamicin. Additionally, is also possible to print medical devices using higher percentage of 405 
drugs. Thus, for example, Genina et al. [37] 3D-printed drug-loaded intrauterine devices using 406 
different grades of ethylene vinyl acetate containing 5% and 15% of indomethacin. 407 
PLA pellets coated with 1 wt% gentamicin were used to fabricate mesh prototypes for hernia 408 
repair [38]. In this study, they obtained a zone of inhibition of 1.1 ± 0.1 cm2 for E coli and 1.2 ± 0.1 cm2 409 
for S aureus. In a different work, polyvinyl alcohol (PVA) 3D meshes loaded with iodine were 410 
manufactured and these also showed a zone of inhibition against E. coli and S. aureus [39]. These 411 
results were far below to those found in our work. The diameter of the zone of inhibition in the S. 412 
aureus plates with TPU meshes of 0.25% LFX was 25.5 ± 1.4 mm and 28.6 ± 0.8 mm for meshes 413 
containing 1% LFX. As mentioned above, there were no significance differences between these results 414 
and the ones obtained in the E. coli plates (p > 0.05). Therefore, it can be inferred that even the lower 415 
concentration (0.25%) of LFX had a significant zone of inhibition on both bacterial stains, which 416 
further minimises the risk of toxicity.  417 
The use of medical devices such as transvaginal meshes, catheters or ventilators could be 418 
associated with the development of “nosocomial” or “health-care associated infections” (HCAIs) 419 
[40,41]. Although bacteria, viruses or fungal parasites can cause these infections, bacteria are the most 420 
common pathogens responsible for HCAI. Among these, bacterial species as S. aureus and E. coli have 421 
a major impact [42]. S. aureus is one of the most important pathogens responsible for nosocomial 422 
infections [43]. Moreover, E. coli is an emerging nosocomial pathogen, which is the leading cause of 423 
urinary tract infections (UTI) while, S. aureus is rarely found in these infections [43,44]. These 424 
infections may result in prolonged stays in the different health-care facilities, such as hospitals while 425 
increasing health-care costs [45]. Hence, the use of these 3D-printed meshes could decrease the rate 426 
of bacterial infections caused by the implant. 427 
The majority of the FDM applications describing the combination of polymers with drugs are 428 
focused on the development of oral solid dosage forms [46,47]. We believe that this technology has 429 
potential to be used for the manufacturing of medicated devices that can be produced on demand for 430 
a patient before a specific treatment/surgery. Previously we reported the use of FDM for dialysis 431 
catheter manufacturing [14,19] or antioxidant wound dressings. Some preliminary work has been 432 
done about the use of 3D printing for mesh implant manufacture. However, these works were not 433 
realistic as they propose the use of materials such as PLA or PCL that are biodegradable and do not 434 
present appropriate mechanical properties for this task [38,48,49]. Some of these works incorporated 435 
some antibiotics to the material. However, these works were not realistic due to material selection, 436 
but these studies worked as a proof of concept showing the potential of 3D printing for this purpose. 437 
Additionally, some recent work described the potential of using FDM as a tool for mesh implant 438 
manufacturing using PP [50]. The limitations of this material have been described previously. 439 
Moreover, these authors incorporated ciprofloxacin into the meshes by dip coating the implants. This 440 
is not ideal as the manufacturing involves a two-step process. In the present work, the mesh is 441 
produced directly containing the drug within the device. 442 
Further research needs to be conducted about the in vivo biocompatibility of the meshes and 443 
shape optimization to adapt the mechanical properties of the mesh to patient’s needs. The present 444 
work is a proof of concept that shows the potential of FDM technology to prepare elastic anti-infective 445 
materials. Finally, there are still regulatory aspects that should be addressed before 3D printing can 446 
be approved as a manufacturing technology for surgical devices. The US FDA has published some 447 
guidelines to manufactures about the appropriate use of this technology [51]. 448 
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